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Abstract
Osteoarthritis (OA), a chronic disease characterized by articular cartilage degeneration, is a leading cause of disability
and pain worldwide. In OA, chondrocytes in cartilage undergo phenotypic changes and senescence, restricting
cartilage regeneration and favouring disease progression. Similar to other wound-healing disorders, chondrocytes
from OA patients show a chronic increase in the gap junction channel protein connexin43 (Cx43), which regulates
signal transduction through the exchange of elements or recruitment/release of signalling factors. Although immature
or stem-like cells are present in cartilage from OA patients, their origin and role in disease progression are unknown. In
this study, we found that Cx43 acts as a positive regulator of chondrocyte-mesenchymal transition. Overactive Cx43
largely maintains the immature phenotype by increasing nuclear translocation of Twist-1 and tissue remodelling and
proinflammatory agents, such as MMPs and IL-1β, which in turn cause cellular senescence through upregulation of
p53, p16INK4a and NF-κB, contributing to the senescence-associated secretory phenotype (SASP). Downregulation of
either Cx43 by CRISPR/Cas9 or Cx43-mediated gap junctional intercellular communication (GJIC) by carbenoxolone
treatment triggered rediferentiation of osteoarthritic chondrocytes into a more differentiated state, associated with
decreased synthesis of MMPs and proinflammatory factors, and reduced senescence. We have identified causal Cx43-
sensitive circuit in chondrocytes that regulates dedifferentiation, redifferentiation and senescence. We propose that
chondrocytes undergo chondrocyte-mesenchymal transition where increased Cx43-mediated GJIC during OA
facilitates Twist-1 nuclear translocation as a novel mechanism involved in OA progression. These findings support the
use of Cx43 as an appropriate therapeutic target to halt OA progression and to promote cartilage regeneration.
Introduction
Osteoarthritis (OA), a chronic disorder characterized by
the progressive degradation of articular cartilage, is the
most prevalent and disabling musculoskeletal disease
worldwide1,2. Osteoarthritic cartilage exhibits changes in
its extracellular matrix (ECM) composition caused by
alterations in component synthesis and degradation3,4.
Cartilage ECM mainly comprises proteoglycans and col-
lagen type II (Col2A1) and embedded chondrocytes; these
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cells have low mitotic activity, but high metabolic activity
due to their role in ECM remodelling. However, in the
early stages of OA, osteoarthritic chondrocytes (OACs)
undergo phenotypic changes that increase cell prolifera-
tion and cluster formation, with enhanced expression of
matrix-remodelling enzymes reflecting attempts to repair
the damage. Disruption of the pericellular matrix and
progressive cartilage degradation together with changes in
subchondral bone, synovial and other joint tissues are
characteristic features of disease progression that are
associated with increased pain and physical disability5,6.
The underlying mechanisms of OA are poorly under-
stood and none of the current pharmacological treat-
ments can slow or stop disease progression. However,
drugs that promote chondrogenic differentiation in
in vitro and in vivo disease models indicate that OACs
somehow revert to a less differentiated stage7–10. Different
molecular hallmarks of OA include the presence of
markers of an immature cell phenotype11–15, suggesting
that these cells retain a degree of flexibility7. Cell ded-
ifferentiation and reprogramming are associated with
wound healing and tissue regeneration16–18. Indeed, bio-
logical conditions such as tissue injury and ageing pro-
mote a precise spatiotemporal cellular plasticity and
in vivo reprogramming to achieve tissue repair19. How-
ever, changes in cell plasticity can also cause pathological
processes, such as fibrosis and tumour progression20–23.
Consistent with other wound-healing diseases, we have
found that osteoarthritic cartilage has very high levels of
the transmembrane protein connexin43 (Cx43)24,25. By
coordinating cellular communication through hemi-
channels (cell-extracellular milieu), gap junctions (GJs;
cell–cell) and extracellular vesicles and tunnelling nano-
tubes, Cx43 plays a key role in many cell functions,
including cell proliferation, migration and differentiation
in cancer and during development and tissue remodel-
ling26–29. Because, Cx43 is involved in wound healing and
inflammation, we investigated whether Cx43 might play
similar roles during tissue degeneration and repair in OA.
Indeed, the normalization of wound healing in skin and
heart tissue correlates with Cx43 downregulation at dif-
ferent time points after wounding, which accelerates
healing (via modulation of proliferation and migration)
and reduces inflammation and fibrosis, promoting a
more normal structure with improved mechanical prop-
erties30–33. Therefore, the chronic overexpression of Cx43
in OA patients due to activation of the wound-healing
response may maintain chondrocytes in a more immature
(i.e., fibrogenic) phenotype that enables the constant ECM
remodelling that leads to cartilage degeneration. This is
consistent with (i) Cx43 overexpression from the early
stage of the disease24, (ii) the presence of proliferative
chondrocytes in osteoarthritic cartilage and (iii) the typi-
cal observation that cartilage is gradually replaced by
fibrocartilage with poor biomechanical properties, which
leads to joint degeneration34–39.
The role of connexins in clinical conditions such as
inflammation and tissue regeneration has recently gained
increased interest. In this study, we focus on how Cx43
affects the phenotype of OACs. Our results reveal a novel
role for Cx43 in coordinating cell dedifferentiation and
redifferentiation in OA to manage ECM remodelling and
to restrain senescence and inflammation. Among the
cascade of events leading to OACs reprogramming,
upregulation of Cx43 increases the degree of cellular
dedifferentiation towards an immature state. Thus, drugs
targeting Cx43 to induce redifferentiation may protect
against cartilage degradation in OA and boost
regeneration.
Results
OACs acquire a stem-like phenotype
To test whether immature chondrocytes contribute to
OA pathogenesis, we first asked whether chondrocytes
isolated from OA patients express stemness-associated
cell surface markers (Fig. 1). Using flow cytometry, we
characterized the expression of the extracellular markers
CD90, CD105, CD29, CD44, CD166 and CD73 during
chondrogenic differentiation of human mesenchymal
stem cells (hMSCs). As expected, most immature markers
decreased during differentiation of hMSCs towards
chondrocytes for 7 and 14 days (Fig. 1a). However, high
levels of stemness markers such as CD166 were detected
on the surface of the OACs (Fig. 1b). In addition, OACs in
monolayer culture continued to dedifferentiate to an even
more immature phenotype40,41 correlating with increased
levels of the stemness markers CD105, CD44 and CD166
(Fig. 1b and Supplementary Fig. 1). The expression of
CD166 indicated that OACs maintained a higher degree
of dedifferentiation in long-term culture versus chon-
drocytes from healthy donors (Fig. 1c). Moreover, CD166
levels were significantly higher in OACs from grade III to
IV OA than in those from low-grade OA (Fig. 1d).
To verify this stem-like feature of chondrocytes from
OA patients, primary chondrocytes were cultured in
chondrogenic medium. We detected a significant reduc-
tion in the levels of stemness markers after 14 days in
chondrogenic culture (Fig. 1e). In addition, the levels of
the transmembrane protein Cx43, previously suggested to
be involved in chondrocyte dedifferentiation42, decreased
significantly during growth of OACs in chondrogenic
medium for 7 and 14 days (Fig. 1f). The cellular plasticity
of OACs was further confirmed using 3D cultures to test
cartilage matrix composition and organization. Surpris-
ingly, pellet culture of OACs in chondrogenic medium led
to micromasses with characteristic features of healthy
cartilage, with high levels of ECM containing proteogly-
cans and collagen type II (Col2A1) and reduced levels of
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Cx43 (Fig. 1g and Supplementary Fig. 2a). Pellet culture of
healthy chondrocytes in chondrogenic medium improved
Col2A1 and proteoglycans synthesis, but to a lesser extent
in comparison with OACs (Supplementary Fig. 2b). The
reverted phenotype and cellular plasticity acquisition of
OACs were confirmed by maintenance of primary cells on
chamber slides in osteogenic medium or adipogenic
medium (Fig. 1h). Osteogenic and adipogenic differ-
entiation were tested by alizarin red S and oil red O
staining, respectively. The results indicated that OACs
have high cellular plasticity and ability to differentiate into
adipocytes and bone cells (Fig. 1h). However, the ability of
healthy chondrocytes to differentiate into adipocytes or
bone cells was significantly lower compared with OACs
(Fig. 1h). As expected, because these (healthy) chon-
drocytes were previously expanded in monolayer43–45, we
also detected immature-like characteristics. The findings
were consistent with the results shown in Fig. 1b.
Fig. 1 OAC reverts to a more progenitor-like or stem cell-like phenotype. a Mesenchymal stem cell markers (CD90, CD105, CD29, CD44, CD166
and CD73) were tracked by flow cytometry for 7 and 14 days during chondrogenic differentiation of hMSCs in monolayer culture. Data were
normalized to the 0-day value. b Dedifferentiation of OAC to a more progenitor-like cell state at different time periods in monolayer culture was
quantified with the same stem cell markers and flow cytometry. Data were normalized to those of low passage numbers (<1 month; S1). Cell
populations of unstained cells (Unst; negative control) and during short (<1 month; S1) and long (>2 months; S2) passages are shown on the right.
The heterogeneous subpopulations of dedifferentiated OAC (red line, S1 passage) tended to reach a single population of dedifferentiated
chondrocytes cells after long passages (blue line, S2). c Comparative flow cytometry analysis showing that OACs express higher levels of the stem cell
marker CD166 compared with chondrocytes isolated from healthy donors (n= 5–8; mean ± s.e.m.; ***P < 0.0001; one-way ANOVA). d Increased
CD166 levels detected by flow cytometry in OACs from high-grade (grades III–IV) versus low-grade (grades I–II) OA donors (n= 4–5; mean ± s.e.m.; *P
< 0.05; Mann–Whitney test). e Expression of stem markers by flow cytometry when OACs are cultured in chondrogenic medium (CM) for 14 days
suggests that dedifferentiated OACs can redifferentiate into mature chondrocytes (n= 2; mean ± s.e.m.; ***P < 0.0001, Student’s t-test). f Cx43 protein
levels in OACs cultured for 7 and 14 days in normal growth medium (DMEM with 10% FBS; UT) or in chondrogenic medium (CM) (n= 4; mean ± s.e.
m.; *P < 0.05; Student’s t-test). g Representative images of OACs that have undergone chondrogenic differentiation (CM) as 3D micromasses for
30 days, and evaluated with Safranin O/Fast Green staining and Col2A1 immunohistochemistry. h Comparative images of OACs and healthy
chondrocytes (N) that have undergone adipogenic (AM, evaluated by Oil red O staining) or osteogenic (OM, evaluated by alizarin red staining)
differentiation for 21 days (AM; adipogenic induction medium, OM; osteogenic medium) OACs show more plasticity and ability to differentiate into
adipocytes and bone cells (representative of n= 10 experiments; mean ± s.e.m.; *P < 0.05, ***P < 0.0001; Mann–Whitney test). Original magnifications
×20, ×40 and ×100. Scale bars are shown below
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Reduced Cx43-mediated GJIC improves the phenotype of
OACs
Cx43 protein is upregulated in OA24. We next exam-
ined whether GJIC was also altered in chondrocytes from
OA patients (Fig. 2a). OACs showed higher levels of Cx43
protein (detected by immunofluorescence, western blot
and flow cytometry). Cx43 in primary chondrocytes is
localized in appositional membranes as expected for gap
junction plaques (Fig. 2a) and OACs showed increased
GJIC (detected by LY transfer) compared with healthy
chondrocytes (Fig. 2b). Next, we assessed whether inter-
cellular coupling via GJ channels affected the OACs
Fig. 2 Downregulation of Cx43 GJ plaques and GJIC restores chondrocyte redifferentiation in chondrocytes from patients with OA. a OACs
express higher levels of Cx43 protein (mainly located in GJ plaques, white arrows) compared with chondrocytes from healthy donors (N), (western
blot, flow cytometry and immunofluorescence assays (n= 3; mean ± s.e.m.; *P < 0.05; Mann–Whitney test). b OACs show higher levels of GJIC in
comparison with healthy chondrocytes in primary cultures measured by SL/DT assay (n= 3; mean ± s.e.m.; *P < 0.05; Mann–Whitney test). c Flow
cytometry analysis shows reduced levels of CD105 and CD166 in OACs treated for 7 days with 100 μM CBX, suggesting reduced chondrocyte
dedifferentiation upon GJIC inhibition. Graphs show CD105 and CD166 levels detected in OACs exposed to CBX or chondrogenic medium (CM) (n=
4–5; mean ± s.e.m.; *P < 0.05, **P < 0.01, ***P < 0.0001; one-way ANOVA). d OACs in chondrogenic (CM) and normal growth medium (UT, DMEM 10%
FBS) for 48 h. GJCI was measured by SL/DT assay (n= 3; mean ± s.e.m.; ***P < 0.0001; Mann–Whitney test). e CBX 50 and 100 μM inhibit GJIC in OACs
measured by SL/DT assay (Supplementary Fig. 3a). Immunofluorescence analysis of Col2A1 and Cx43 levels in OACs treated with CBX 50 and 100 μM
for 24 h. The graphs show the percentage of positive cells for Col2A1 and the CTCF for Cx43 mainly located in the margin of the cells (gap junction
plaques, white arrows) (n= 5; mean ± s.e.m.; *P < 0.05, **P < 0.01; one-way ANOVA). f Adipogenic differentiation of OACs exposed to CBX 50 μM for
21 days was evaluated with oil red O staining. The graph represents the ratio of cells with lipid deposits to the total number of cells (n= 8, mean ± s.
e.m.; ***P < 0.0001; Mann–Whitney test). g IL-1ß, IL-6, COX-2, MMP-3 and MMP-13 mRNA expression in OACs treated with 50 and 100 μM CBX for
15 min. Data were normalized to HPRT-1 (n= 3–4; mean ± s.e.m.; *P < 0.05, **P < 0.01, ***P < 0.0001; one-way ANOVA)
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phenotype. Chondrocytes from OA patients were treated
with 100 μM of the GJ blocker carbenoxolone (CBX),
which inhibits GJIC46–49 (Supplementary Fig. 3a) or were
grown in chondrogenic medium for 7 days (Fig. 2c).
Compared with the untreated condition, OACs treated
with CBX showed lower levels of the surface stemness
markers CD105 and CD106 (Fig. 2c and Supplementary
Fig. 3b), and similar to chondrogenic medium conditions,
suggesting that the positive effect of Cx43 downregulation
on the OACs phenotype also depends on Cx43 channel
activity. Interestingly, the chondrogenic medium reduced
Cx43 protein levels (Fig. 1f) and GJIC (Fig. 2d).
Next, we sought to confirm whether inhibition of GJIC
would modulate chondrocyte plasticity. OACs were
grown in monolayer in growth medium supplemented
with 50 μM and 100 μM of CBX (Fig. 2e). Consistent with
previous results (Fig. 2c), downregulation of GJIC by CBX
improved the phenotype of OACs detected by a sig-
nificant increase in the levels of Col2A1 (Fig. 2e). CBX
also decreased Cx43 protein levels at the gap junction
plaque as detected by immunofluorescence (Fig. 2e). To
further explore the effect of Cx43 plaques and GJIC on
cell plasticity, OACs were grown in adipogenic medium in
the presence of 50 μM CBX. Notably, inhibition of GJIC
by CBX significantly decreased the adipogenic differ-
entiation of OACs as detected by oil red O staining
(Fig. 2f). However, CBX treatment increased the osteo-
genic differentiation of OACs when these cells were
grown in osteogenic medium with 50 μM CBX for 14 days
(Supplementary Fig. 4). Consistent with this finding,
previous studies have suggested a direct transformation of
mature chondrocytes into osteoblasts and osteocytes50–52,
reemphasizing the role of Cx43 as a modulator of cell
plasticity in chondrocytes, whose downregulation enhan-
ces OACs redifferentiation to mature chondrocytes. As
expected, redifferentiation of OACs by reducing Cx43
plaques and GJIC with CBX (Fig. 2c, e) led to reduced
expression of the proinflammatory mediators IL-1ß, IL-6
and COX-2 and reduced levels of MMP-3 and MMP-13
(Fig. 2g).
Cx43 promotes phenotypic reversion by modulating Twist-1
Transfection of the T/C-28a2 human chondrocyte cell
line with a Cx43 overexpression vector significantly
increased Cx43 protein levels, Cx43 membrane localiza-
tion, GJIC (Fig. 3a) and levels of the stemness surface
markers CD166 and CD105 (Fig. 3b). Similarly, reduction
of Cx43 levels in the T/C-28a2 human chondrocyte cell
line by CRISPR/Cas9-mediated heterozygous Cx43 gene
knockout led to a downregulation of the GJIC (Fig. 3c)
and the stemness surface markers CD166 and CD105
(Fig. 3d).
The reversion of the cell phenotype in OACs can be
regulated by several mechanisms, including transcription
factors involved in the epithelial-to-mesenchymal transi-
tion (EMT) such as Twist-1. In addition, Twist-1 is a
regulator of MSCs differentiation into chondrocytes53 and
is expressed in immature chondrocytes but decreased in
mature chondrocytes54. In addition, Twist-1 is upregu-
lated in human OA knee cartilage55. Significantly, over-
expression of Cx43 in chondrocytes led to nuclear
translocation of Twist-1, as detected by western blot,
together with an increase in nuclear PCNA, which is
associated with cell proliferation (Fig. 3e). The increase in
Twist-1 was accompanied by an elevated expression of the
EMT markers N-cadherin and vimentin (Fig. 3e) and with
changes in the vimentin cytoskeleton and cell shape
(Fig. 3f). Notably, the mRNA expression levels of N-cad-
herin, vimentin and Twist-1 were significantly reduced
when Cx43 was downregulated in the heterozygous Cx43
gene knockout cell line. Downregulation of Cx43 pre-
vented from nuclear localization of Twist-1 (Fig. 3g).
Downregulation of Cx43 protects OACs from senescence
and inflammation
Dedifferentiation can be induced by various stress
conditions and has the potential to accelerate ageing
processes56,57. Moreover, increased cellular senescence
was recently reported in OA cartilage58. In accordance
with these results, we observed that high levels of Cx43
were correlated with increased cellular senescence in
human chondrocytes (T/C-28a2), as detected by the
senescence-associated beta-galactosidase (SAβG) activity
measured by flow cytometry (Fig. 4a). To verify that
altered Cx43 expression leads to senescence, we studied
changes in the replicative senescence factor p53 and its
signalling partner p16INK4a. Gene expression and western
blot analysis revealed increased levels of p53 and p16INK4a
when Cx43 was overexpressed (Fig. 4b). In addition, cel-
lular senescence and the senescence-associated secretory
phenotype (SASP) can convert senescent cells into
proinflammatory cells. Increased levels of Cx43 were
sufficient to induce higher expression of proinflammatory
mediators involved in cartilage degradation in OA, such
as IL-1β, COX-2 and the metalloproteinases 3 and 13
(Fig. 4c). As expected, upregulation of Cx43 activated NF-
κß (nuclear translocation), a master regulator of the SASP
(Fig. 4d). Hence, a reduction in Cx43 levels via the
CRISPR/Cas9 approach (T/C-28a2 cells heterozygous for
Cx43) decreased the levels of nuclear NF-κß (Fig. 4d),
together with a significant reduction in the levels of
chondrocyte senescence detected by SAβG activity and
p53/p16INK4a levels (Fig. 4e). Downregulation of
Cx43 significantly reduced the synthesis of the inflam-
matory and cell reprogramming factors IL-1ß and IL-6
and the ECM remodelling enzymes MMP-3 and MMP-13
(Fig. 4f). Taken together, these results suggest that over-
expression of Cx43 contributes to dedifferentiation of
Varela-Eirín et al. Cell Death and Disease (2018)9:1166 Page 5 of 16
Official journal of the Cell Death Differentiation Association
Fig. 3 Upregulation of Cx43 induces Twist-1 activation and switches on the dedifferentiation program to gain mesenchymal
characteristics. a The T/C-28a2 chondrocyte cell line transfected with a plasmid to overexpress Cx43 (referred to as Cx43) displays increased Cx43
protein levels (detected by western blot) and GJIC (evaluated by LY transfer in an SL/DT assay). Cx43 levels were compared with those of the non-
transfected and empty vector (EV)-transfected cells. The graph represents the quantification of more than 10 images from two independent
experiments (*P < 0.05; Mann–Whitney test). Below, immunofluorescence assays indicating that, in chondrocytes overexpressing Cx43, Cx43 (green) is
mainly localized to the membrane (red arrows) and perinuclear area (white arrows). Nuclei were stained with DAPI. b Flow cytometry analysis
showing that T/C-28a2 cells overexpressing Cx43 (red) expressed significantly higher levels of the stemness markers CD105 (n= 7) and CD166 (n= 5)
versus the same cell line transfected with a control plasmid (black) (mean ± s.e.m.; *P < 0.05; Mann–Whitney test). c Downregulation of Cx43 levels in
T/C-28a2 cells with the CRISPR-Cas9 knockdown system (Cx43−/+) (detected by western blot) led to significantly lower levels of GJIC, detected by SL/
DT assay (n= 6, mean ± s.e.m.; **P < 0.01; Mann–Whitney test). d Compared with the control cells, the CRISPR-Cas9 knockdown chondrocyte cell line
(T/C-28a2, Cx43−/+) contained lower levels of the stem cell markers CD105 (flow cytometry) and CD106 (flow cytometry, western blot and RT-qPCR).
Flow cytometry; n= 7 mean ± s.e.m.; *P < 0.05, **P < 0.01; Mann–Whitney test. Gene expression was normalized to HPRT-1 levels (n= 7, mean ± s.e.
m.; ***P < 0.0001; one-way ANOVA). e Upregulation of Cx43 increases the levels of nuclear Twist-1 and nuclear PCNA (western blot) and upregulates
the gene expression of Twist-1 and the mesenchymal markers vimentin and N-cadherin (RT-qPCR, below) (n= 3–5; mean ± s.e.m, *P < 0.05;
Mann–Whitney test). T/C-28a2 cell line overexpressing Cx43 compared with non-transfected cells or control plasmid (EV). Lamin A was used as a
nuclear loading control. f Changes in the vimentin (red) filament network were associated with Cx43 upregulation. T/C-28a2 cells overexpressing
Cx43 versus non-transfected cells. Nuclei were stained with DAPI. Scale bar is shown below. g Reduced levels of Cx43 in T/C-28a2 cells (CRISPR-
cas9 system) correlated with downregulation of N-cadherin, vimentin and Twist-1 gene expression (n= 3, mean ± s.e.m.; *P < 0.05; Mann–Whitney
test). Cx43 levels correlated with nuclear levels of Twist-1 and PCNA, detected by western blot. T/C-28a2 cell line compared to the same cells
overexpressing Cx43 (Cx43) or the heterozygous for Cx43 (Cx43−/+). Lamin A was used as a nuclear loading control (n= 2–3, mean ± s.e.m.; *P < 0.05,
**P < 0.01; Student’s t-test)
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chondrocytes in OA (chondrocyte-mesenchymal transi-
tion via Twist-1), but also favours an inflammatory
environment and premature senescence, which in the
long term may contribute to excessive tissue remodelling
and degradation.
Discussion
During OA, chondrocytes undergo dedifferentiation
and senescence, but how these processes are activated and
coordinated is poorly understood. Herein, we demon-
strate that the GJ channel protein Cx43 acts as a positive
regulator that reverts chondrocytes to a less differentiated
state, possibly by upregulating the activity of factors such
as the basic helix-loop-helix transcription factor Twist-1
(Fig. 3) and inflammatory cytokines such as IL-1β (Fig. 4).
Overexpression of Cx43 and enhancement of GJIC in
OACs compromises the ability of these cells to rediffer-
entiate, promoting (and prolonging) a stem-like state by
activating chondrocyte-mesenchymal transition. How-
ever, this is a reversible loss, because downregulation of
Cx43 and GJIC allow chondrocytes to properly execute
the redifferentiation program. In previous studies, OACs
were shown to have a compromised ability to rediffer-
entiate in monolayer and 3D culture59,60. Our findings
suggest a new paradigm in which the dedifferentiation
and redifferentiation of chondrocytes are regulated by a
Cx43-sensitive circuit. Similarly, in an intracerebral hae-
morrhage mouse brain model Cx43 was recently shown to
regulate a phenotypic switch by activation astroglial-
mesenchymal transition via nuclear translocation of the
Yes-associated protein (YAP), a potent transcription
coactivator61. Cx43 was found to sequester YAP at gap
Fig. 4 Dedifferentiation induced by Cx43 activates senescence and prolongs inflammation and remodelling. a Flow cytometry analysis with
the FDG substrate showing elevated levels of SAβG activity in Cx43-overexpressing T/C-28a2 cells (red) versus empty vector (EV) control cells (black)
(n= 5; mean ± s.e.m.; *P < 0.05; Mann–Whitney test). b Western blot (n= 2; mean ± s.e.m.; *P < 0.05; Student’s t-test) and RT-qPCR (n= 4; mean ± s.e.
m.; *P < 0.05; Mann–Whitney test) showing that overexpression of Cx43 increased p53 and p16 levels in T/C-28a2 chondrocytes. c Analysis of IL-1β,
COX-2, MMP-3 and MMP-13 mRNA levels using real-time PCR in T/C-28a2 cells overexpressing Cx43 (n= 2–4; normalized to HPRT-1 and represented
as mean ± s.e.m.; *P < 0.05; Mann–Whitney test). d Nuclear levels of NF-κB detected by western blot in the T/C-28a2 cell line overexpressing Cx43
(Cx43) and in the T/C-28a2 heterozygous for Cx43 (Cx43−/+), compared to the non-transfected cell line (T/C-28a2). Lamin A was used as a nuclear
loading control (n= 2, mean ± s.e.m.; *P < 0.05, **P < 0.01; Student’s t-test). e Downregulation of Cx43 in T/C-28a2 cells (CRISPR-Cas9 knockdown)
decreased SAβG (blue) (n= 3–4; mean ± s.e.m. *P < 0.05, **P < 0.01; one-way ANOVA), and increased of p53 and p16 protein levels, detected by
western blot (n= 2–3, mean ± s.e.m.; *P < 0.05; Student’s t-test). f Analysis of IL-1β, COX-2, MMP-3 and MMP-13 mRNA levels in the T/C-28a2
heterozygous for Cx43 (Cx43−/+). Data were normalized to HPRT-1 (mean ± s.e.m. n= 3–4; *P < 0.05; Mann–Whitney test)
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junction plaques, and downregulation of Cx43 caused
Cx43-YAP complex dissociation and nuclear transloca-
tion of YAP61.
Although progenitor-like cells have been found in dif-
ferent zones of adult cartilage, the origin and functions of
these cells are poorly understood. Based on multilineage
potential and stemness markers, it has been accepted that
these cells act as stem cells within the cartilage62–64.
Further findings indicated the emergence of stem-like
cells in healthy cartilage explants in response to blunt
mechanical impact or scratch injury65. In addition, these
stem-like cells show a distinct phenotype versus hMSCs
isolated from the same donors65. Additional evidence
strongly suggested that the phenotype of these stem cells
is correlated with the degree of ECM degradation in
cartilage from OA patients66,67. Our data support the
hypothesis that these cells, more than stem/progenitor
cells (i.e., hMSCs), are chondrocytes dedifferentiated
towards a stem-like state via EMT. In accordance with our
results, CD166-positive chondrocytes have strong chon-
drogenic potential15. In addition, chondrocytes isolated
from cartilage have chondrogenic, osteogenic and adipo-
genic differentiation potential (Fig. 1)11,68.
Here, we show that overexpression of Cx43 is sufficient
to increase the nuclear translocation of the EMT tran-
scription factor Twist-1 in the established healthy human
chondrocyte cell line T/C-28a2, together with an increase
in vimentin, N-cadherin and the stemness markers CD105
and CD166 (Fig. 3). The phenotypic change is accom-
panied by increased expression of metalloproteinases
(MMP-13 and MMP-3) and proinflammatory mediators
(IL-1β and COX-2) (Fig. 4). Hence, downregulation of
Cx43 or GJIC in chondrocytes (via targeted heterozygous
deletion using CRISPR technology and CBX treatment)
reduces stemness markers and improves Col2A1 synthesis
(Fig. 2) together with a decrease in the expression of
metalloproteinases and proinflammatory mediators
(Fig. 4). Our demonstration that downregulation of Cx43
can rescue the differentiation of OACs may provide
important insights into the conflicting differentiation
status during OA and aid in the development of effective
therapeutic strategies to stop or reverse joint damage.
Although the mechanisms by which Cx43 regulates
OACs dedifferentiation/redifferentiation require further
investigation, we observed that Cx43 overexpression
increased the nuclear levels of Twist-1, leading to
increased cell proliferation and upregulation of the EMT
markers vimentin and N-cadherin (Fig. 3). Following
injury, the dedifferentiation and redifferentiation pro-
cesses play important roles in the generation of pro-
liferating regenerative cells with the ability to restore the
lost tissue in a precise way69,70. Interestingly, Twist-1 has
been linked to muscle regeneration through dediffer-
entiation by downregulating myogenin gene expression
and reversing cell differentiation in the absence of growth
factors71. Undoubtedly, understanding of how Cx43
coordinates tissue regeneration would have therapeutic
implications for cartilage conditions, as has been shown
for skin wound healing72–74 and bone remodelling75. Co-
treatment of OACs with the GJIC-inhibitor CBX affected
the redifferentiation capacity of OACs (Fig. 2), indicating
that connexin channels and GJIC participate in the acti-
vation and nuclear translocation of Twist-1 and the
expression of cytokines. However, inhibition of GJIC by
CBX also decreased Cx43 plaques (Fig. 2e and Supple-
mentary Fig. 5). Together, our results on the inhibition of
dye transfer and downregulation of Cx43 in CBX-treated
chondrocytes suggest that chondrocyte redifferentiation
observed upon CBX treatment occurred through a GJ-
dependent manner (Cx43 plaques). However it is difficult
to exclude Cx43 GJ-independent mechanisms in these
phenotypic switching because CBX also reduced the levels
of Cx43. In fact, and in concordance with our results, it
has been recently reported that a smaller carboxy-
terminal fragment of Cx43 (Cx43-20K) is a transcrip-
tional regulator of N-cadherin by interacting with the
RNA polymerase II and with several transcription factors,
including BTF3 at the N-cadherin gene promoter
region76. Importantly, it has also been reported that Cx43
modulates gene transcription by altering the recruitment
of the Sp1/Sp3 transcription factors to CT-rich connexin-
response elements (CxREs) within promoters77,78. The
promoters of Twist-1 and Col2A1 have Sp1-binding sites
and are modulated by the Sp1/Sp3 complex79–81. Notably,
reduction in Cx43 at the membrane and attenuation of
GJIC in a rat osteoblast-like osteosarcoma cell line (ROS
17/2.8) resulted in reduced Sp1 recruitment to CxREs
through decreased Sp1 phosphorylation by the ERK
mitogen-activated protein kinase (MAPK) cascade78.
Additionally, novel loci recently associated with OA in a
large GWAS include components such as MAP2K6 on
chromosome 17, which is related to the MAPK pathway82,
which can interfere with Cx43 trafficking, stability,
channel function and signalling83,84.
As mentioned above, chondrocytes in culture undergo
dedifferentiation via EMT and senescence. Increased
senescence was recently observed in mice after traumatic
OA, peaking 2 weeks after injury58. While dedifferentia-
tion is seen in early passages, a higher number of senes-
cent cells are observed in late passages compared with
early passages85. Transplantation of such dedifferentiated
and senescent cells results in the formation of unwanted
fibrous cartilage at the transplantation site86,87. The
identification of the mechanisms involved in in vitro and
in vivo redifferentiation to a chondrocyte-specific phe-
notype such as modulation of Cx43 function is needed to
efficiently develop these therapies. On the other hand,
senescent cells have also been suggested to be a promising
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target for improving cartilage regeneration after articular
joint injury in mice58. Indeed, treatment of human OACs
in monolayer and 3D pellet culture with the senolytic
drug UBX0101 for 4 days improves chondrocyte-specific
properties, increasing the levels of COL2A1 and pro-
teoglycans and decreasing the OA-related genes MMP-13
and IL-1β and the senescence-related genes MMP-3 and
IL-658. Here, we show that downregulation of Cx43 also
decreases the propensity of chondrocytes to undergo
cellular senescence. Accordingly, upregulation of Cx43
leads to senescence, along with upregulation of p53/p16,
which has been associated with chondrocyte senes-
cence58,88, and to nuclear translocation of NF-κB, the
master regulator of SASP. In this context, in the same way
downregulation of Cx43 prevents senescence, NF-κB
activation and cytokine/MMPs gene expression (Fig. 4).
IL-1α and IL-1β, through cell surface receptors, act as
upstream regulators of NF-κB and SASP by activating
numerous genes, including those encoding IL-6, IL-8 and
proinflammatory cytokines that reinforce senescence89–94.
Notably, Cx43 overexpression alone in chondrocytes leads
to a fivefold increase in IL-1β gene expression, which is a
catabolic factor in OA (Fig. 4c)95–97. Indeed, IL-1β upre-
gulates Cx43 in chondrocytes and synoviocytes from
patients with OA and rheumatoid arthritis98–100, as well
as p53101,102 and NF-κB90,103. Thus, IL-1β may act as a
feedback loop factor to amplify the effect of Cx43 on
senescence and chondrocyte phenotypic changes in OA.
Among these feedback loop amplification events, it is
important to note that the Twist-1 promoter has a func-
tional NF-κB binding site and that overexpression of NF-
κB is sufficient to induce transcriptional upregulation of
Twist-1, along with EMT and stemness properties104.
Transient induction of cell senescence as part of a
damage response orchestrates tissue remodelling and
repair by promoting dedifferentiation, proliferation and
ECM remodelling105–107. Dysregulated wound healing
caused by excessive signalling and accumulation of
senescent cells, resulting from either excessive production
or defective clearance, acts as a barrier to effective
repair107–109. SASP factors convert senescent cells into
proinflammatory cells110. Importantly, IL-6 and other
soluble factors that strongly promote cellular plasticity by
activating cellular reprogramming in nearby non-
senescent cells105,107,109,111 probably halt redifferentia-
tion by potentiating the chronic dedifferentiation of
chondrocytes in OA. In fact, it has recently been reported
that targeting of the gp130 receptor for the IL-6 family
and activation of ERK and NF-κB improves cartilage
healing in an animal model of OA112. Our discovery that
Cx43 regulates dedifferentiation/redifferentiation, in
addition to senescence, highlights an important intersec-
tion between chondrocyte reprogramming and wound
healing relevant for understanding the molecular basis of
cartilage degeneration in OA, which offers opportunities
for new therapies.
OACs in the cartilage of patients with early- and late-
stage OA are characterized by Cx43 overexpression. Our
study shows that Cx43 causes chondrocyte-mesenchymal
transition and senescence that culminate in cartilage
degeneration. Mechanisms that establish redifferentiation
(chondrocyte-specific phenotype), such as Cx43 down-
regulation, will potentially restore cartilage repair in OA
and improve our ability to implement cell therapy
approaches for cartilage diseases. The present work
demonstrates that control of cellular plasticity and
senescence in chondrocytes via the single master factor
Cx43, which upregulates Twist-1/IL-1β and p53/p16-NF-
κB-IL-6 signalling pathways (Fig. 5), may be an attractive
candidate for tissue engineering and regenerative medi-
cine strategies for OA treatment and for promotion of
proper cartilage repair.
Methods
Tissue collection, processing and cell culture
Cartilage collection and processing were performed as
previously described25. The study was conducted with the
approval of the institutional ethics committee (C.0003333,
2012/094 and 2015/029) and after informed consent were
obtained. We selected samples from healthy and from
moderate OA (grades I–II) and high OA (grades III–IV)
groups. OA samples were assigned based on individuals’
medical record data and histological analysis as previously
described24. Healthy individuals suffered a knee or hip
fracture and had no history of joint disease. Normal tissue
was studied by histological analysis24. Cartilage was
obtained in situ from 35 donors including healthy and OA
patients (grades I–II and grades III–IV). For the isolation
and culture of primary chondrocytes, fresh cartilage was
rinsed with saline and cells were isolated as previously
described113. Cells (2 × 106) were then seeded into 100-
mm dish plates and incubated at 37 °C with 5% CO2 and
100% humidity in Dulbecco’s Modified Eagle’s medium
(DMEM) supplemented with 100 U/ml penicillin, 100 μg/
ml streptomycin and 10% foetal bovine serum (FBS; all
from Gibco, Thermo Fisher Scientific) until ~80–90%
confluence was reached. The T/C-28a2 chondrocyte cell
line, kindly donated by Dr. Goldring (the Hospital for
Special Surgery, New York, USA), was cultured in DMEM
supplemented with 10% FBS, 100 U/ml penicillin and
100 μg/ml streptomycin. hMSCs were obtained with
informed consent from bone marrow donors recruited by
the Bone Marrow Transplant Programme of the Hae-
matology Service at the Hospital Universitario Reina Sofía
(Córdoba, Spain) and from subcutaneous inguinal fat
obtained with signed informed consent from healthy
individuals who underwent catheter insertion at the
Hospital Universitario Ramón y Cajal (Madrid, Spain).
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hMSCs were cultured in α-minimum essential medium
(α-MEM; Lonza) supplemented with 10% FBS, 100 U/ml
penicillin, 100 μg/ml streptomycin, 2 mM GlutaMax
(Gibco, Thermo Fisher Scientific) and 1 ng/ml recombi-
nant human fibroblast growth factor-2 (rhFGF-2; Immu-
notools) or in MesenPRO RSTM Medium supplemented
with 100 U/ml penicillin and 100 μg/ml streptomycin.
Adipogenic differentiation
Confluent cells were incubated with a commercially
available adipogenic medium (AM, hMSC Adipogenic
Differentiation BullekitTM, Lonza) for 21 days, changing
the medium every 2–3 days. Adipogenic differentiation
was evaluated by the oil red O staining. Briefly, lipid
droplets in cells were stained for 20min in freshly pre-
pared and filtered 60% (v/v) oil red O solution prepared
from a 0.5 mg/ml stock (Sigma-Aldrich). Then, cells were
rinsed with 60% (v/v) isopropanol, followed by a final
rinse in dH2O. Slides were imaged using an Olympus
BX61 microscope and a DP71 digital camera (Olympus).
Lipid droplet-containing cells were counted with ImageJ
software version 1.48 and adipogenic differentiation was
evaluated as the ratio of positive droplet-containing cells
to the total number of cells.
Osteogenic differentiation
Chondrocytes or hMSCs were cultured until confluent
and differentiated for 21 days with a commercial
Fig. 5 Downregulation of Cx43 in OA fosters a pro-regenerative environment by favouring redifferentiation. Accumulation of
dedifferentiated (2) and senescent (3) chondrocytes and Cx43 overexpression are typical in the cartilage microenvironment from the early stages of
OA. Phenotypic changes associated with upregulation of Cx43 during tissue repair may contribute to ECM remodelling and cartilage regeneration (or
wound healing) (1–2 and 4, black arrows). However, they result in a chondrocyte fibrogenic phenotype (2, and red arrow) and accumulation of
senescent cells (3) in OA, which is unable to support the ECM composition by continuous activation of ECM remodelling (MMPs) and
proinflammatory factors, such as IL-1ß, NF-κB and IL-6 a, c. Downregulation of Cx43 or GJIC (e.g., by CRISPR-Cas9 or CBX treatment) leads to
redifferentiation of OACs (4) by reducing Twist-1 activation (2), senescence (3 and b) and SASP (c, NF-κB-p65). The results indicate that
dedifferentiation and senescence in OA are flexible processes that can be reverted by modulating Cx43. The elimination or inhibition of factors that
contribute to the prolongation of cellular dedifferentiation (Twist-1; chondrocyte-mesenchymal transition) or reprogramming (e.g. via IL-6) reduces
the burden of dedifferentiated (2) and senescent (3) cells, which in turn decreases the synthesis of catabolic factors (a and c) involved in cartilage
degradation in OA and leads to a mature phenotype able to support the cartilage ECM composition
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osteogenic medium (StemPro® Osteogenesis Differentia-
tion Kit, Gibco, Thermo Fisher Scientific). The medium
was changed every 2–3 days. Osteogenesis was evaluated
by calcium deposit formation with alizarin red S staining.
Acetone-fixed cells were stained with a 2% (w/v) alizarin
red S solution (Sigma-Aldrich) for 5 min at room tem-
perature (RT) and rinsed with dH2O. Slides were imaged
using an Olympus BX61 microscope and a DP71 digital
camera (Olympus). Alizarin red positivity was analysed
using ImageJ software version 1.48.
Chondrogenic differentiation
Chondrogenesis was induced in chondrocytes or
hMSCs with a commercial chondrogenic medium
(StemPro® Chondrogenesis Differentiation Kit, Gibco,
Thermo Fisher Scientific). For flow cytometry analysis of
chondrogenesis, cells were cultured as a monolayer for 7
and 14 days in the presence of chondrogenic medium. A
total of 25,000 cells seeded into 8-well culture chambers
were used for chondrogenesis, osteogenesis and adipo-
genesis assays. The differentiation in monolayer started
when cells reached 90% confluence (after 2 days in cul-
ture). For immunohistochemical analysis, cells were cul-
tured as micromasses (500,000 cells per pellet) for 30 days
in the presence of chondrogenic medium. Micromasses
were embedded in Tissue-Tek® OCT™ (Sakura) and
chondrogenesis was evaluated with the ECM-specific
stains toluidine blue, safranin O-fast green and Col2A1
immunohistochemistry.
Western blot
Cells were lysed in ice-cold lysis buffer (150 mM NaCl,
50 mM Tris-HCl, pH 7.5, 5 mM EDTA, pH 8, 0.5% v/v
Nonidet P-40, 0.1% (w/v) SDS, 0.5% (v/v) sarkosyl) sup-
plemented with 5 μg/ml protease inhibitor cocktail and
1mM phenylmethylsulfonyl fluoride (PMSF; Sigma-
Aldrich). For nuclear protein isolation, the NE-PERTM kit
(Thermo Fisher Scientific) was used according to the
manufacturer’s instructions. Total protein content was
determined by a Bradford protein assay. Ten micrograms
of total protein was separated on 10% SDS-PAGE and
transferred to a polyvinylidene fluoride (PVDF) mem-
brane (Millipore Co., Bedford, MA). Protein transfer was
checked by staining the membrane with ATX Ponceau S
red staining solution (Sigma-Aldrich). The membrane was
then blocked with 5% milk in Tris-buffered saline (TBS;
20 mM Tris, 150 mM NaCl) and 0.05% Tween-20 (Sigma-
Aldrich) and incubated with primary antibody overnight
at 4 °C; HRP-secondary antibody incubation was per-
formed at RT for 1 h. The signal was developed using
PierceTM ECL Western Blotting Substrate in an LAS-300
Imager (Fujifilm). The following primary antibodies were
used: α-tubulin (Sigma-Aldrich, T9026), Cx43 (Sigma-
Aldrich, C6219), Twist-1 (Santa Cruz Biotechnology, sc-
81417), PCNA (Santa Cruz Biotechnology, sc-56), CD166
(Santa Cruz Biotechnology, sc-74558), p16INK4a (Abcam,
ab108349), p53 (Santa Cruz Biotechnology, sc-126), NF-
κB (Santa Cruz Biotechnology, sc-8008) and lamin A
(Santa Cruz Biotechnology, sc-20680).
Scrape loading/dye transfer (SL/DT) assay
An SL/DT assay was performed to evaluate GJIC as
previously described with modifications25. Cells were
seeded on 12-well culture plates and cultured until
70%–100% confluent. Cells were rinsed twice with warm
PBS and a 0.4% (w/v) solution of lucifer yellow (LY) (Cell
Projects Ltd©, Kent, UK) in PBS was loaded. Then, two
distant scrapes were made across the culture plate with a
29-gauge needle and scalpel and the cells were allowed to
take up the dye for 3 min at 37 °C. After being washed
twice with FBS-free DMEM, the cells were fixed with 4%
formaldehyde and dye transfer was evaluated in a Nikon
Eclipse Ti fluorescent microscope with a ×10 objective
lens. The number of dye-positive cells (LY transfer) from
the cut site to the farthest detectable uptake of LY reflects
the GJ connectivity between cells. The score was calcu-
lated as previously reported114,115.
Antigen expression analysis by flow cytometry
For the detection of membrane-associated epitopes, cells
were fixed with 1% paraformaldehyde at RT for 10min.
Then, cells were washed with a flow cytometry (FCM)
buffer (PBS pH 7.2, 0.5% bovine serum albumin (BSA),
2mM EDTA) and incubated with a mix of conjugated
antibodies for 30min at 4 °C in the dark. When a wide
range of markers were analysed, we used a kit containing a
combination of different conjugated monoclonal antibodies
(CD90-FITC, CD105-PE, CD29-APC, CD44-FITC, CD166-
PE, CD73-APC) (Immunostep, MCK-50T). Later, phy-
coerythrin (PE)-conjugated anti-human CD105 (Immuno-
step, 105PE-100T) and allophycocyanin (APC)-conjugated
anti-human CD166 (Immunostep, 1399990314) were cho-
sen for cell characterization. After the antibody incubation,
the cells were washed twice and resuspended in 100–200 μl
FCM buffer. For the detection of membrane and intracel-
lular epitopes, the cells were collected, washed twice with
PBS and fixed with 1% paraformaldehyde at RT for 10min.
Then, the cells were washed twice with PBS and permea-
bilized with 900 μl chilled (−20 °C) methanol (VWR Che-
micals) for 30min at 4 °C. Next, two washes with PBS were
performed and the cells were kept in FCM buffer for 30min
prior to the antibody incubation. After being pelleted at
600 g for 7min at 4 °C, the cells were resuspended in 100 μl
of cold staining buffer with unconjugated monoclonal
mouse anti-collagen II antibody (Invitrogen, Thermo Fisher
Scientific, MA5-12789) or with APC-conjugated anti-
human Cx43 antibody (R&D Systems, FAB7737A) for
30min at 4 °C in the dark. When unconjugated primary
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antibodies were used, after two washes with the staining
buffer, the cells were incubated with R-phycoerythrin
(RPE)-conjugated goat anti-mouse antibody (DAKO,
R0480) for 30min at 4 °C in the dark. As a final step, the
cells were washed twice with cold FCM buffer and resus-
pended in 100–200 μl of the same buffer until analysis.
Flow cytometry analysis
Cells were analysed on a BD Accuri C6 (Becton Dick-
inson,) and/or a BD FACSCaliburTM (Becton Dickinson)
flow cytometer. Cell debris was discriminated by the
forward scatter (FSC) and side scatter (SSC) properties of
the cells, and cell aggregates were removed from the
analysis by the selection of single cells using the area
versus high signal of FSC, as described in Supplementary
Fig. 6a. Between 5,000 and 20,000 events were collected in
the single scatter gate region and data were analysed with
FCS Express 6 Flow software (De Novo Software). The
level of positive staining was expressed as the median
fluorescence intensity or as a stain index by weighting the
fluorescence with the standard deviation of each sample.
Negative controls were unlabelled cells. Compensation
was performed using antibody capture beads (the com-
pensation matrix can be found in Supplementary Fig. 6b).
Gates were placed based on single-labelled controls and
by establishing 0.1% as the cutoff point.
Senescence-associated β-galactosidase activity
SAβG activity was assessed by flow cytometry with the
fluorogenic β-galactosidase substrate di-β-D-galactopyr-
anoside (FDG; Invitrogen, Thermo Fisher Scientific),
which is hydrolyzed by cell endogenous β-galactosidase to
fluorescein (FITC). Cells were collected and incubated in
staining medium (PBS, 4% FBS, 10 mM HEPES, pH 7.2) at
37 °C for 10 min. The β-galactosidase assay was started by
adding pre-warmed 2mM FDG to the cell suspension and
performing a 3-min incubation at 37 °C in the dark. The
reaction was stopped with the addition of ice-cold stain-
ing medium to the cells, which were kept on ice and
protected from light until analysis.
Immunofluorescence
Cells were fixed with 2% (w/v) paraformaldehyde
(Sigma-Aldrich) in PBS for 10min at RT and then incu-
bated for an additional 10 min at RT with 0.1M glycine
(Sigma-Aldrich). Cell membranes were permeabilized by
incubation with 0.2% Triton X-100 (Sigma-Aldrich) in
PBS for 10min at RT. After a PBS wash, cells were
incubated for 30min at RT with 1% BSA (Sigma-Aldrich)
in PBS supplemented with 0.1% (v/v) Tween-20 (PBST;
Sigma-Aldrich). Primary antibodies were diluted in 1%
BSA in PBST and incubated for 1 h at RT. Three 10-min
washes with PBS were performed and the cells were
incubated with secondary antibody (diluted in 1% BSA in
PBST) for 1 h at RT in the dark. The cells were washed
three times with PBS, and nuclei were stained with 1 μg/
ml 4’,6-diamidino-2-phenylindole dihydrochloride (DAPI;
Sigma-Aldrich) for 4 min at RT in the dark. After three
PBS washes, the coverslips were mounted with a drop of
glycergel aqueous mounting medium (Dako) on a glass
microscope slide. The following primary antibodies were
used: anti-Cx43 (Sigma-Aldrich, C6129), anti-collagen II
(Invitrogen, Thermo Fischer Scientific, MA5-12789) and
anti-vimentin (Santa Cruz Biotechnology, sc-373717).
Goat anti-rabbit FITC-conjugated (F-2765) and goat anti-
mouse Alexa 594-conjugated (A-11032) secondary anti-
bodies were used (both from Invitrogen, Thermo Fisher
Scientific). Fluorescence was analysed by using ImageJ
software version 1.48 and is shown as the corrected total
cell fluorescence (CTCF).
Immunohistochemistry
Acetone-fixed 4-μm-thick sections of cell micromasses
were rinsed twice with PBS and non-specific endogenous
peroxidase activity was quenched with a 3% (v/v) hydro-
gen peroxidase (H2O2) solution (Roche) for 10min. The
samples were washed twice with PBS and primary anti-
body was applied for 1 h at RT. The slides were then
washed three times with PBS and incubated with Opti-
View HQ Universal Linker (Roche) for 10min at RT.
After three additional washes with PBS, the slides were
incubated with OptiView HRP Multimer (Roche) for
8 min at RT. After two more washes with PBS, peroxidase
activity was developed using a 0.02% H2O2 and 0.1% DAB
solution. The sections were then washed in distilled water
and, in some cases, counterstained with Gill’s hematoxylin
(Merck Millipore). As a final step, the slides were gradu-
ally dehydrated with alcohol, cleared with xylene (Pan-
Reac AppliChem) and mounted with DePeX (BDH Gun®,
VWR).
Immunohistochemistry analysis
An in-house developed MATLAB program was used to
quantify the immunohistochemistry images. This pro-
gram first splits RGB images into single channels and
applies a three-level automatic thresholding to the green
channel using Otsu’s method116. Then, it segments the
images into four discrete classes using the threshold
levels. Finally, the total pixels are obtained from the seg-
mented images belonging to the three darker classes by
discarding the lightest level in the image (background).
Quantitative PCR
Total RNA was isolated from cells using TRIzolTM
reagent (Invitrogen, Thermo Fisher Scientific) according
to the manufacturer’s instructions. The RNA was treated
with RNase-free DNase (Invitrogen, Thermo Fisher
Scientific) to ensure the degradation of DNA in the
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samples. One microgram of total RNA per reaction was
used to synthesize cDNA with the SuperScript® VILO™
cDNA Synthesis Kit as instructed by the manufacturer
(Invitrogen, Thermo Fisher Scientific). Quantitative PCR
was performed with the Applied BiosystemsTM Power-
UPTM SYBRTM Green Master Mix from Applied Bio-
systems on a real-time PCR instrument (LightCycler®
480 System, Roche) using the primers listed in Supple-
mentary Table 1.
Cell transfection
The T/C-28a2 chondrocyte cell line was transfected
with a pIRESpuro2 plasmid construct (Clontech) con-
taining the human Cx43 sequence, kindly provided by
Arantxa Tabernero (Institute of Neuroscience of Castilla y
León, University of Salamanca, Salamanca, Spain). Briefly,
106 cells were electroporated with either 3 μg of pIRES-
Cx43 plasmid or the pIRESpuro2 plasmid as control.
Electroporation was performed with the Amaxa® Cell
Line Nucleofector® Kit V (Lonza) in a NucleofectorTM 2b
device (Lonza) following the manufacturer’s instructions.
Transfected cells were selected by supplementing the
culture medium with 0.1 μg/ml puromycin dihy-
drochloride (Tocris).
CRISPR/Cas9 system
T/C-28a2 cells were electroporated with the Amaxa®
Cell Line Nucleofector® Kit V (Lonza) in a Nucleo-
fectorTM 2b device with 2 μg of a transitory all-in-one
CRISPR expression vector (modified version of Addgene
plasmid #48138) containing the VP12 high-fidelity Cas9
enzyme (derived from Addgene plasmid #72247) linked to
a GFP marker via a 2A-self-cleaving peptide, with a guide
targeting 20 nucleotides near the initial part of exon 2 of
the Cx43 gene (5′-ACAGCGGTTGAGTCAGCCTG-3′).
Single electroporated cells were seeded into a 96-well
plate and GFP+ clones were selected and expanded in
conditioned medium (50% v/v medium from non-
transfected T/C-28a2 cells). Dot blot and western blot
analyses to check Cx43 levels were used to select the
clones for further study.
Statistical analysis
Data were analysed using GraphPad Prism software
(version 5.00). Mean analysis of two groups was per-
formed using either the Student’s t-test or the
Mann–Whitney U-test, whereas the mean of more than
two groups was analysed with the one-way ANOVA with
Tukey post hoc test. P < 0.05 was considered statistically
significant.
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